PMHNP Specialty Billing
Spravato (Esketamine) Billing For PMHNPs
A Spravato session usually bills as two parts: the drug, reported with a drug code and units, and the in-office administration and monitoring, reported separately. Before either one pays, the setting has to be REMS-certified, the payer usually wants prior authorization, and you need to know whether the drug comes through buy-and-bill or a specialty pharmacy.
Why It Is Different
Spravato Is Not A Standard Office Visit
Esketamine, sold as Spravato, is administered in a certified healthcare setting under a federal risk program, and the patient is monitored on site for a required period after each dose. That changes the billing. A Spravato session generally has a drug component and a separate administration and monitoring component instead of one visit code, and it carries requirements a routine medication management visit doesn’t, like prior authorization and specific documentation.
Codes and units change, so this guide sticks to the structure and points you to the sources that confirm the current values. For the routine visit codes, see the PMHNP billing and coding guide.
Program Context
The REMS Program And In-Office Administration
Spravato is dispensed and administered under a Risk Evaluation and Mitigation Strategy, or REMS, a program the FDA requires for certain medications with safety concerns. In practice, it isn’t something a patient picks up and takes at home. It’s given in a certified setting, and the practice, prescriber and pharmacy all have to be enrolled in the program.
Certified Setting
Administration happens in a healthcare setting enrolled in the REMS program, with the patient self-administering the nasal spray under supervision. Enrollment and program requirements come first. They’re prerequisites, not billing details.
Supervised Monitoring Period
After dosing, the patient is monitored on site for a required period, commonly described as around two hours, before being discharged. That monitoring time is a core part of the service and needs to be documented.
Documentation Matters
Because the service is time-bound and safety-driven, records of administration, monitoring, vital signs, and the discharge decision support both patient safety and the claim. Thin documentation is a common source of denials on complex services.
The Components
Separate Drug And Administration Components
A Spravato session generally isn’t billed as one line. There’s a component for the drug itself and a separate one for administering it and monitoring the patient. Get that split right, along with how each payer handles each side, and you’ve got the foundation for getting paid correctly.
The Drug Component
The medication is reported using the appropriate drug code and units. The exact code, unit definition, and any required detail vary and change over time, so get current requirements from CMS and the specific payer rather than relying on a figure you saw somewhere.
The Administration And Monitoring Component
The in-office administration and the supervised monitoring period are reported separately from the drug. How you code it, and whether time and supervision requirements apply, depends on the payer, so get the current definitions from AMA CPT and the payer.
Do Not Rely On Specific Codes Here
We don’t list J-codes, CPT codes or dollar amounts on this page, and that’s on purpose. They differ by payer and get updated, and since a stale code is a fast route to a denial, pull the current values from the authoritative source and the payer for the date of service every time.
Access And Payment
Prior Authorization And How You Source The Drug
Two operational decisions shape a Spravato program’s economics and cash flow: getting treatment authorized before you deliver it, and how you’ll get and pay for the drug. Settle both before your first patient. Either one can create large, avoidable financial exposure.
| Consideration | What to Plan For |
|---|---|
| Prior authorization | Spravato commonly requires authorization before administration. Confirm each payer’s requirements and criteria in advance; a missing authorization is often a non-appealable denial. |
| Buy-and-bill | The practice purchases the drug, keeps it in inventory, administers it, and bills the payer. This puts the acquisition cost and reimbursement risk on the practice, so cash flow and denial management matter. |
| Specialty pharmacy | The drug is supplied through a specialty pharmacy for the specific patient, so the practice bills primarily for the administration and monitoring rather than the drug. This shifts drug cost and inventory off the practice. |
| Which model applies | The choice is often driven by the payer and the plan, not solely by preference. Confirm what each payer allows or requires before committing to a sourcing approach. |
| Documentation and units | Whichever path you’re on, accurate records of the drug, units, administration and monitoring time support the claim. Get current unit and code requirements from CMS, AMA CPT and the payer. |
Spravato sessions repeat, and so do the authorization and sourcing checks behind each one. That’s why many programs keep a per-patient tracker of authorization dates and sessions used right next to the schedule.
Common Questions
Frequently Asked Questions
How Is Spravato Billing Different From A Normal Psychiatric Visit?
A Spravato session generally has separate drug and administration components rather than a single visit code, includes a required supervised monitoring period that must be documented, and typically involves prior authorization and REMS program participation. It’s more operationally involved than routine medication management.
What Is The REMS Program And Why Does It Matter For Billing?
REMS stands for Risk Evaluation and Mitigation Strategy, an FDA-required safety program. Spravato must be administered in a certified setting by enrolled participants, so enrollment and its documentation requirements are prerequisites that underpin a clean, supportable claim.
What Codes And Amounts Should I Use For Spravato?
We don’t publish specific J-codes, CPT codes or dollar amounts, because they vary by payer and change over time, and a stale code causes denials. Confirm the current drug code, units, administration coding and reimbursement with CMS, AMA CPT and the specific payer for the date of service.
Does Spravato Require Prior Authorization?
It commonly does, but requirements and criteria are set by each payer and plan. Check the specific authorization requirements before you administer, since a missing or expired authorization is often a denial you can’t appeal, and the practice doesn’t get paid.
What Is The Difference Between Buy-And-Bill And Specialty Pharmacy?
With buy-and-bill, the practice purchases and stocks the drug, administers it, and bills the payer, carrying the acquisition cost and reimbursement risk. With specialty pharmacy, the drug is supplied for a specific patient and the practice mainly bills the administration and monitoring. The payer often dictates which applies.
How Much Of The Monitoring Time Needs To Be Documented?
The supervised monitoring after dosing is a core, safety-driven part of the service, so records of administration, monitoring, vital signs, and the discharge decision are important for both patient safety and the claim. Follow the current clinical and payer requirements for what to capture.
Running Spravato Next To Everything Else?
An Automation Program builds one workflow into the systems your team already uses. For a specialty program like Spravato, TMS or ketamine, that means scheduling by room and observation time, authorization and REMS tracking, reminders and reporting. It’s $5,000, or 4 monthly payments of $1,250. For the drug and administration claims, see our billing prices by practice size.
This is general information, not billing, legal, tax or medical advice, and it isn’t clinical guidance on administering esketamine. Codes, coverage, prior-authorization rules and reimbursement vary by payer and change over time, so get the specifics from CMS, AMA CPT, the payer, the manufacturer’s REMS program and a qualified professional. Last reviewed: July 2026.